Becton Dickinson income statement
In fiscal 2025, Becton Dickinson reported revenue of $21.84bn, up 8.2% on the year before, operating income of $2.58bn (a 11.8% margin) and net income of $1.68bn, or $5.82 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.
Income statement
| Fiscal year | 2009Sept 2009 | 2010Sept 2010 | 2011Sept 2011 | 2012Sept 2012 | 2013Sept 2013 | 2014Sept 2014 | 2015Sept 2015 | 2016Sept 2016 | 2017Sept 2017 | 2018Sept 2018 | 2019Sept 2019 | 2020Sept 2020 | 2021Sept 2021 | 2022Sept 2022 | 2023Sept 2023 | 2024Sept 2024 | 2025Sept 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.0 | 7.1 | 7.6 | 7.7 | 8.1 | 8.4 | 10.3 | 12.5 | 12.1 | 16.0 | 17.3 | 16.1 | 19.1 | 18.9 | 19.4 | 20.2 | 21.8 | 23.3 |
| Cost of revenue | 3.3 | 3.4 | 3.6 | 3.8 | 3.9 | 4.1 | 5.6 | 6.5 | 6.1 | 8.7 | 9.0 | 9.3 | 10.5 | 10.4 | 11.2 | 11.1 | 11.9 | 12.3 |
| Gross profit | 3.7 | 3.7 | 4.0 | 4.0 | 4.2 | 4.3 | 4.7 | 6.0 | 5.9 | 7.3 | 8.3 | 7.6 | 8.6 | 8.5 | 8.2 | 9.1 | 9.9 | 10.9 |
| Research and development | 0.4 | 0.4 | 0.5 | 0.5 | 0.5 | 0.6 | 0.6 | 0.8 | 0.8 | 1.0 | 1.1 | 1.0 | 1.3 | 1.3 | 1.2 | 1.2 | 1.3 | 1.4 |
| Selling, general and administrative | 1.7 | 1.7 | 1.8 | 1.9 | 2.4 | 2.1 | 2.6 | 3.0 | 2.9 | 4.0 | 4.3 | 4.2 | 4.7 | 4.7 | 4.7 | 4.9 | 5.3 | 5.7 |
| Operating income | 1.6 | 1.6 | 1.7 | 1.6 | 1.3 | 1.6 | 1.1 | 1.4 | 1.5 | 1.5 | 1.8 | 0.9 | 2.3 | 2.3 | 2.1 | 2.4 | 2.6 | 2.5 |
| Interest expense | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.4 | 0.4 | 0.5 | 0.7 | 0.6 | 0.5 | 0.5 | 0.4 | 0.5 | 0.5 | 0.6 | 0.6 |
| Income before tax | 1.6 | 1.6 | 1.6 | 1.5 | 1.2 | 1.5 | 0.7 | 1.1 | 1.0 | 1.2 | 1.2 | 0.4 | 1.7 | 1.8 | 1.7 | 2.0 | 1.9 | 2.0 |
| Income tax | 0.4 | 0.5 | 0.4 | 0.4 | 0.2 | 0.3 | 0.0 | 0.1 | −0.1 | 0.9 | −0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.3 | 0.2 | 0.2 |
| Net income | 1.2 | 1.3 | 1.3 | 1.2 | 1.3 | 1.2 | 0.7 | 1.0 | 1.1 | 0.3 | 1.2 | 0.9 | 2.1 | 1.8 | 1.5 | 1.7 | 1.7 | 0.9 |
| Diluted EPS | $4.87 | $5.49 | $5.62 | $5.59 | $6.49 | $5.99 | $3.35 | $4.49 | $4.60 | $0.60 | $3.94 | $2.71 | $6.85 | $5.88 | $4.94 | $5.86 | $5.82 | $3.33 |
| Diluted shares (average) | 253m | 246m | 232m | 214m | 204m | 203m | 213m | 223m | 229m | 271m | 282m | 282m | 292m | 287m | 288m | 291m | 289m | 283m |
| EBITDA | 2.1 | 2.1 | 2.2 | 2.1 | 1.8 | 2.2 | 2.0 | 2.5 | 2.6 | 3.5 | 4.0 | 3.0 | 4.5 | 4.5 | 4.4 | 4.7 | 5.0 | 5.0 |
| Quarter | 2024 Q4Sept 2024 | 2025 Q1Dec 2024 | 2025 Q2Mar 2025 | 2025 Q3Jun 2025 | 2025 Q4Sept 2025 | 2026 Q1Dec 2025 | 2026 Q2Mar 2026 | 2026 Q3Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5,437 | 5,168 | 4,480 | 4,726 | 8,301 | 5,252 | 4,714 | 4,983 |
| Cost of revenue | 2,950 | 2,933 | 2,619 | 2,491 | 4,269 | 2,841 | 2,560 | 2,668 |
| Gross profit | 2,487 | 2,235 | 1,861 | 2,235 | 4,032 | 2,411 | 2,154 | 2,315 |
| Research and development | 302 | 343 | 232 | 230 | 559 | 306 | 249 | 258 |
| Selling, general and administrative | 1,256 | 1,318 | 1,117 | 1,163 | 1,843 | 1,393 | 1,213 | 1,261 |
| Operating income | 622 | 453 | 383 | 739 | 1,174 | 552 | 93 | 663 |
| Interest expense | 155 | 155 | 150 | 152 | 155 | 153 | 149 | 132 |
| Income before tax | 514 | 306 | 201 | 569 | 975 | 393 | 39 | 554 |
| Income tax | 114 | 3 | 43 | 118 | 52 | 11 | 76 | 102 |
| Net income | 400 | 303 | 308 | 574 | 493 | 382 | −311 | 377 |
| Diluted EPS | $1.37 | $1.04 | $1.07 | $2.00 | $1.72 | $1.34 | −$1.11 | $1.37 |
| EBITDA | 1,208 | 1,060 | 950 | 1,314 | 1,930 | 1,166 | 656 | 1,227 |
Compare with peers
- GE HealthCare income statement
- Boston Scientific income statement
- Stryker Corporation income statement
- Koninklijke Philips NV income statement
- Medtronic income statement
Head to head: BDX vs GEHCBDX vs BSXBDX vs SYK
More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies